CHU Dijon Bourgogne
Dijon, 21079, France
NCT Number: NCT02857452
The evaluation of lupus patients must include several approaches, in particular disease activity and quality of life.
The Systemic Lupus Activity Questionnaire (SLAQ) is a validated self-questionnaire to evaluate disease activity. It has the advantage of being inexpensive, easy to use in large cohorts and has been used in several studies. It has never been validated in French. The Lupus Quality Of Life (LupusQoL) is a self-questionnaire to evaluate quality of life and is specific to systemic lupus erythematous; it was developed from interviews with patients.
This tool, validated in a British population, has never been validated in French.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Observational
Dijon, 21079, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Evolution of answers between D0, D15, M3 and M6
Time frame: Evolution of answers between D0, D15, M3 and M6
Centre Hospitalier Universitaire Dijon
Other
Acronym: FRESH COLA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06013995
Autoimmune Diseases, Connective Tissue Diseases
San Diego, California, United States
View Trial DetailsNCT03093402
Autoimmune Diseases, Connective Tissue Diseases
La Jolla, California, United States
View Trial DetailsNCT07267091
Autoimmune Diseases, Connective Tissue Diseases
Montreal, Quebec, Canada
View Trial DetailsNCT06872138
Biomarker, Female Urogenital Diseases
Giza, Egypt
View Trial Details